EMA grants Orphan Drug Designation for Setmelanotide for treatment of acquired hypothalamic obesity
The European Medicines Agency (EMA) has issued a positive opinion on the Rhythm Pharmaceuticals’ orphan drug designation request for...
EMA grants Orphan Drug Designation for Setmelanotide for treatment of acquired hypothalamic obesity
The pandemic, obesity and people with bipolar disorders
Altimmune completes dosing in the Phase 2 MOMENTUM trial
First patients treated with ECLIPSIUM hernia repair system
Barbed sutures are as safe as conventional sutures for closing RYGB anastomotic defects
RACP calls for increased access to bariatric surgeries and medicines
Reinforcing bariatric patients’ beliefs about their own competences helps them achieve their goals